
|Articles|June 22, 2011
- Psychiatric Times Vol 28 No 6
- Volume 28
- Issue 6
Einstein’s Happiest Moment -for Susanne
Author(s)Richard M. Berlin, MD
"Einstein’s happiest moment...occurred when he realized...a falling man falling...beside a falling apple..."
Advertisement
POETRY OF THE TIMES
Einstein’s happiest moment
occurred when he realized
a falling man falling
beside a falling apple
could also be described
as an apple and a man at rest
while the world rises around them.
And my happiest moment
occurred when I realized
you were falling for me,
right down to the core, and the rest,
relatively speaking, has flown past
faster than the speed of light.
Articles in this issue
about 15 years ago
Feeling Socially Safeabout 15 years ago
Avoiding SRI Discontinuation Syndromeabout 15 years ago
Drs McGlashan and Woods Respond to Dr Feinbergabout 15 years ago
Obama Drug Misuse Strategy Targets Physician Educationabout 15 years ago
Alfred M. Freedman, MD, 1917-2011about 15 years ago
Is It Treatment-Refractory Schizophrenia . . . And if It Is?about 15 years ago
Are We Training Psychiatrists to Provide Only Medication Management?about 15 years ago
Effects of Early Parental DepressionAdvertisement
Related to this article

FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.

Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.

Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.

Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.

Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
3
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
4
New Analyses of HLP003 for the Adjunctive Treatment of MDD
5

